Multiple Sclerosis

CAMBRIDGE, Mass. -- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the European Medicines Agency (EMA) has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme([R])...

ePharma Consumer ([R] ) Study Reveals New Trends around How Consumers Interact with Pharma, Including Customer Service Options, Patient Education, and Pharma Websites - Webinar January 25 at 2pm ET NEW YORK --...

THE WOODLANDS, Texas -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin([R]), a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will...

NEW YORK & PETACH TIKVAH -- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced that the data from the...

MIAMI BEACH, Fla. -- Although using angioplasty to treat multiple sclerosis (MS) is highly controversial, sufferers often insist it helps - in some cases dramatically, such as allowing them to walk without a...

HEADNOTE Lobbyist Cites Concern Over Reforms to Come HEALTHCARE Anew Bloomberg Government study shows that although insurance companies spent millions of dollars trying to defeat government healthcare reform, their profit margins have widened...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/b3725d/endpointsclinical) has announced the addition of the "Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma" report to their offering. GBI Research,...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/9eaa07/evolution_in_the_p) has announced the addition of the "Evolution in the Pain Therapy Drugs Market: Nociceptive and Neuropathic Drug Development" report to their offering. "...Who are the players, and...

WESTON, Mass. -- Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year end 2011 financial results on Tuesday, January 31, 2012, before the financial markets open. Following the release...

MARBLEHEAD, Mass. -- Medicinal Genomics, a pioneer in the genomics of medicinal plants, today announced the availability of Jane-Ome, an application designed for Apple's iPad tablet, which offers a science-based dissection of medical...

COLORADO SPRINGS, Colo. -- Cannabis Science, Inc. (OTCBB: CBIS.OB - News), a pioneering US biotech company developing pharmaceutical cannabis products, is happy to report an additional, apparently successful, self-medicated cannabis treatment for a...

Program Provides GenomeQuest Software, Services, and Expertise to Convert and Consolidate Sanger Gene Test Panels WESTBOROUGH, Mass. -- GenomeQuest Inc., a global provider of large-scale genomic software applications, announced today that it has...

* AMPYRA 2011 Q4 Net Sales of $57 Million (unaudited) and 2011 Full-Year Net Sales of $210 Million (unaudited) * AMPYRA 2012 Net Sales Guidance of $255-$275 Million * 2012 Zanaflex and ex-U.S....

Two Former Teva Executives Tailor Personalized Online Customer Self-Service Solutions for Healthcare, Insurance and Pharma Companies SPOKANE, Wash. -- Next IT, a leading provider of Intelligent Virtual Assistants for business, is expanding its...

BENGALURU, India & SAN FRANCISCO -- Biocon (BSE:532523) (NSE:BIOCON) (ISIN:INE376G01013), Asia's premier biotechnology Company, today announced positive results from its Double Blind, Placebo Controlled, Phase 3, TREAT-PLAQ Study with Itolizumab in chronic plaque...

ROCKVILLE, Md. -- RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today announced that it has been issued a patent from the U.S. Patent and Trademark Office claiming methods for...

SAN FRANCISCO -- New Zealand is well known for its wines and stunning scenery, but the country is also a great source of innovation in the life sciences. A delegation of New Zealand...

* Cloud billings1 grew 89% year-over-year * Cloud deferred revenue grew 113% year-over-year * Cloud revenue grew 64% year-over-year * Subscription revenue grew 23% year-over-year; representing 63% of total revenues * Subscription gross...

ROCKVILLE, Md. -- RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") announced today that it has received the clinical study report for its recently completed Phase 2 clinical trial evaluating...